GW501516,GW-501,516,GW1516,GSK-516,Endurobol CAS 317318-70-0

GW501516,GW-501,516,GW1516,GSK-516,Endurobol CAS 317318-70-0

Shot Description:

GW501516,GW-501,516,GW1516,GSK-516,Endurobol CAS 317318-70-0 GW501516 (also known as GW-501,516, GW1516, GSK-516 and on the black market as Endurobol) is a PPARδ receptor agonist that was invented in a collaboration between Ligand Pharmaceuticals and GlaxoSmithKline in the 1990s, was entered into clinical development as a drug candidate for metabolic diseases and cardiovascular diseases, and was abandoned in 2007 because animal testing showed that the drug caused cancer to develop rapidly in several…

Inquiry Now

INQUIRY DETAILS *

INQUIRY DETAILS
  • captcha

Description:

GW501516,GW-501,516,GW1516,GSK-516,Endurobol CAS 317318-70-0

GW501516,GW-501,516,GW1516,GSK-516,Endurobol CAS 317318-70-0

GW501516,GW-501,516,GW1516,GSK-516,Endurobol CAS 317318-70-0

GW501516 (also known as GW-501,516, GW1516, GSK-516 and on the black market as Endurobol) is a PPARδ receptor agonist that was invented in a collaboration between Ligand Pharmaceuticals and GlaxoSmithKline in the 1990s, was entered into clinical development as a drug candidate for metabolic diseases and cardiovascular diseases, and was abandoned in 2007 because animal testing showed that the drug caused cancer to develop rapidly in several organs.

In 2007 research was published showing that high doses of GW501516 given to mice dramatically improved their physical performance; the work was widely discussed in popular media, and led to a black market for the drug candidate and to its abuse by athletes as a doping agent. The World Anti-Doping Agency (WADA) developed a test for GW501516 and other related chemicals and added them to the prohibited list in 2009; it has issued additional warnings to athletes that GW501516 is not safe.

工厂5

GW501516,GW-501,516,GW1516,GSK-516,Endurobol


Tags: